Gemunden, Germany
Gemunden, Germany
SEARCH FILTERS
Time filter
Source Type

News Article | May 18, 2017
Site: www.businesswire.com

BERTRANGE, Luxembourg--(BUSINESS WIRE)--Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its third fund, Vesalius Biocapital III, securing over €65 million of commitments as at 15 May 2017. Until the final closing in 2018, Vesalius Biocapital III will accept new investors on a “rolling closing” basis. Starting immediately, the fund plans to invest in later-stage European life sciences companies across drug development, medtech, diagnostics and digital health, providing capital to support their development. Now in its tenth year, Vesalius Biocapital has raised over €150 million from a renowned investor base for its two previous funds. The firm has completed over 20 investments with lead or co-lead positions, and achieved numerous exits through trade sales and IPO. With a well balanced portfolio between drug development and non-drug development investments, the firm has developed a track-record of strong and consistent financial performance while generating significant returns for its investors. Recent and notable exits include Ogeda (acquired by Astellas for €800 million), Activaero (sold to Vectura for €130 million), Genkyotex (reverse merger on Euronext) and Fovea (acquired by Sanofi for €370 million). Commenting on the first close, Stéphane Verdood, Managing Partner at Vesalius Biocapital III said: “We are very fortunate to have attracted high quality investors to Vesalius Biocapital III in validation of our successful track record. Furthermore, we are glad that a significant number of investors in our previous funds Vesalius Biocapital I and Vesalius Biocapital II are backing us in our new fund. This is an exciting time in healthcare; the industry is at a key inflection point between science, technology and medicine, and our investors support our strategy to invest in companies developing innovative products and technologies.” “While the primary focus is investing in Europe, we want to provide a bridge to enable European companies to access US capital markets, and for North American companies to have access to Europe for development, expansion or access to innovation. To this extent, we have set up a Boston-based US presence to provide support to the portfolio and evaluate new opportunities.” Vesalius Biocapital III will target later-stage European companies in drug development, medtech, diagnostics and eHealth / mHealth, with the goal of investing in 10-15 companies over the lifetime of the fund. Vesalius Biocapital (Vesalius), the specialist life sciences venture capital investor, has supported companies active in human health through venture capital funds since 2007. In the ten years since inception, Vesalius has raised over €150 million in its first two funds, Vesalius Biocapital I and II, and contributed in the development of over 20 companies. The investment portfolio is well balanced between drug development and non-drug development investments and committed to providing capital to science-backed innovation and ambitious entrepreneurs, with a strong focus on exit within five years. The specialist team consists of seasoned life science professionals with healthcare industry, corporate finance and strategy consulting experience, supporting companies through their growth cycle. The team is based in Europe and the USA to explore investment opportunities and valuation potential for the portfolio. For more information: www.vesaliusbiocapital.com New fund Vesalius Biocapital III, launched in April 2017, targets later-stage European life science companies in drug development, medtech, diagnostics and eHealth / mHealth. The fund secured over €65 million of commitments in a first closing in May 2017, with a target size of €150 million. Managing Partners include Guy Geldhof, Marc Lohrmann, Dr Christian Schneider and Stéphane Verdood. Venture Partners are Dr Cees Wortel and Dr David Braga Malta. The Investors Committee comprises independent members Baron Jean Stéphenne M.Sc., M.B.A. (Chairman of the Investors Committee; previously President and General Manager of GSK Biologicals), Dr Hans-Juergen Leuchs (formerly member of the Board of Managing Directors of Boehringer Ingelheim, Ingelheim, Germany), Dr Gaston Matthyssens (Managing Partner Vesalius Biocapital I and Vesalius Biocapital II), Dr Francois Sarkozy (previously co-founder and chairman of Publicis Healthcare Consulting).and Dr Ajit Shetty (until 2012, Chairman of the Board of Directors of Janssen Pharmaceutica, a pharmaceutical company and subsidiary of Johnson & Johnson). For more information on the fund, please visit http://fund3.vesaliusbiocapital.com/


Price D.,University of Aberdeen | Bosnic-Anticevich S.,University of Sydney | Briggs A.,University of Glasgow | Chrystyn H.,University of Huddersfield | And 3 more authors.
Respiratory Medicine | Year: 2013

Whilst the inhaled route is the first line administration method in the management of asthma, it is well documented that patients can have problems adopting the correct inhaler technique and thus receiving adequate medication. This applies equally to metered dose inhalers and dry powder inhalers and leads to poor disease control and increased healthcare costs. Reviews have highlighted these problems and the recent European Consensus Statement developed a call to action to seek solutions. This review takes forward the challenge of inhaler competence by highlighting the issues and suggesting potential solutions to these problems. The opportunity for technological innovation and educational interventions to reduce errors is highlighted, as well as the specific challenges faced by children. This review is intended as a policy document, as most issues faced by patients have not changed for half a century, and this situation should not be allowed to continue any longer. Future direction with respect to research, policy needs and practice, together with education requirements in inhaler technique are described. © 2012 Published by Elsevier Ltd.


Siekmeier R.,University of Bonn | Hofmann T.,Activaero | Scheuch G.,Activaero
Advances in Experimental Medicine and Biology | Year: 2015

Systemic antibiotic treatment is established for many pulmonary diseases, e.g., cystic fibrosis (CF), bronchiectasis and chronic obstructive pulmonary disease (COPD) where recurrent bacterial infections cause a progressive decline in lung function. In the last decades inhalative administration of antibiotics was introduced into clinical routine, especially tobramycin, colistin, and aztreonam for treatment of CF and bronchiectasis. Even though they are important in systemic treatment of these diseases due to their antimicrobial spectrum and anti-inflammatory and immunomodulatory properties, macrolides (e.g., azithromycin, clarithromycin, erythromycin, and telithromycin) up to now are not administered by inhalation. The number of in vitro aerosol studies and in vivo inhalation studies is also sparse. We analyzed publications on preparation and administration of macrolide aerosols available in PUBMED focusing on recent publications. Studies with solutions and dry powder aerosols were published. Publications investigating physicochemical properties of aerosols demonstrated that macrolide aerosols may serve for inhalation and will achieve sufficient lung deposition and that the bitter taste can be masked. In vivo studies in rats demonstrated high concentrations and areas under the curve sufficient for antimicrobial treatment in alveolar macrophages and epithelial lining fluid without lung toxicity. The obtained data demonstrate the feasibility of macrolide inhalation which should be further investigated. © 2014, Springer International Publishing Switzerland.


Methods, devices and compositions for treatment of severe and uncontrolled asthma are provided by which high amounts of an inhaled corticosteroid are directed to the small airways of the lower lungs. The invention provides for a substantial decrease in the dose of concurrently administered oral corticosteroids. A particular advantage of the invention is the significant reduction in corticosteroid-related adverse effects.


Patent
Activaero and Temicon GmbH | Date: 2015-06-24

The invention generally relates to the field of dispensing liquids, and in particular to aerosolizing of fine liquid droplets, for example for delivery of medicinal products to the deeper, peripheral lung. The invention provides perforated membranes with specifically shaped holes, each hole exhibiting two adjacent and preferably coaxially arranged cylindrical longitudinal sections, whose second length is larger than the first length and whose second diameter is larger than the first diameter. Such perforated membranes provide an improved hole diameter precision ( 0.5 m), lower achievable pitch values and/or higher achievable hole densities in order to allow for the generation of very fine aerosols with droplet sizes preferably below 3 m at high throughput rates larger than 0.5 ml/min. The invention further provides a process for the preparation of such perforated membranes and their application in inhalation devices, such as vibrating mesh nebulisers, and for inhalation therapies.


Patent
Activaero | Date: 2014-04-30

The inhalation device comprises a base unit (100), a mouthpiece (200) and an aerosol head (300). The base unit comprises an air inlet (101), an air outlet (102), a groove (103) for receiving the mouthpiece, and key lock members (104). The mouthpiece comprises a first segment (200a) comprising an air inlet (201) and a lateral opening (202) for receiving an aerosol generator, the first segment being insertable into the groove of the base unit, and a second segment (200b) comprising an aerosol outlet (203). The aerosol head comprises an aerosol generator (301), a liquid reservoir (302), and key lock members (303) complementary to the key lock members of the base unit. The base unit, mouthpiece and aerosol head are connectible with one another such that when engaging the members of the key lock with the complementary members, the aerosol generator is inserted into the lateral opening of the mouthpiece.


Patent
Activaero | Date: 2013-10-25

The invention provides an inhalation device comprising a base unit, a mouthpiece, and an aerosol head. The base unit comprises an air inlet, an air outlet opening, a groove for receiving the mouthpiece, and key lock member(s). The mouthpiece comprises a first segment, comprising an air inlet opening and a lateral opening for receiving an aerosol generator, the first segment being insertable into the groove of the base unit, and a second segment comprising an aerosol outlet. The aerosol head comprises an aerosol generator, a liquid reservoir, and key lock member(s) complementary to the key lock member(s) of the base unit. The base unit, mouthpiece and aerosol head are connectable with one another such that when engaging the members of the key lock with the complementary members, the aerosol generator is inserted into the lateral opening of the mouthpiece.


A method of treatment of cystic fibrosis and other pulmonary diseases identified by nitric oxide deficiency, comprising administration of a nebulized solution of citrulline and/or another nitric oxide precursor as an inhalable aerosol or an inhalable dry powder for targeted delivery into conducting and central airways. Citrulline or another nitric oxide precursor is formulated as a composition having predetermined limited volume, salinity, pH and osmolality. The composition is nebulized into an aerosol having a mass median aerodynamic diameter (MMAD) between 2 m and 6 m.


The invention relates to a device for the flow rate limitation at low differential pressures, in particular for the limitation of the inhalation volume flow during the inhalation of therapeutic aerosols, comprising a housing with at least an inlet opening, at least an outlet opening and a flow channel arranged therebetween, wherein the flow channel is restricted by a flexible wall extending along the flow channel, characterised in that the flexible wall has a control area of less than 100 mm^(2).


Loading Activaero collaborators
Loading Activaero collaborators